AMRN collaboration with Mochida (PR’d by both companies in 2018) was to develop MND-2119 (revealed in Mochida PR as noted in my prior posts), so quite sure they have exclusive license.
Among other terms in the agreement, Amarin obtained an exclusive license to certain Mochida intellectual property to advance Amarin’s interests in the United States and certain other territories and the parties will collaborate to research and develop new products and indications based on EPA for Amarin’s commercialization in the United States and certain other territories. The potential new product and indication opportunities contemplated under this agreement are in relatively early stages of development.